BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
| Website: | www.biondvax.com |
| Main Phone: | +972 89302529 |
| Address: | Hadassah Ein Kerem Campus |
| Address 2: | Jerusalem BioPark, 2nd floor |
| City / Town: | Jerusalem |
| Country: | ISR |
| Postal Code: | 74036 |
| Exchange: | NSC |
| CEO: | Ron Babecoff |
| Employees: | 25 |
BiondVax Pharmaceuticals Ltd. announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.
Announced today that enrollment of 224 participants in a Phase 2b clinical trial, the study aims to show the dose sparing potential when given prior to avian vaccine.
All 224 participants successfully recruited in EU-sponsored trial
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will present at the Annual Roth Conference to be held March 13 - 16, 2016 at the Ritz Carlton Hotel in Dana Point, California.
Technical moves always precede Fundamental news and thought it important to point this out...something is in the offing and volume is always an indicator for me and I made a note to call the company.
BiondVax Pharmaceuticals (BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, announced today that its patent application in the United States, titled "Multimeric M
Broadens BiondVax's global intellectual property portfolio
BiondVax Pharmaceuticals announced that their patent application on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines was accepted in Israel.
The patent approval extends and strengthens BiondVax's international intellectual property portfolio
Although flu vaccinations are widely available, they only protect against a very specific strain of flu.
BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
| Website: | www.biondvax.com |
| Main Phone: | +972 89302529 |
| Address: | Hadassah Ein Kerem Campus |
| Address 2: | Jerusalem BioPark, 2nd floor |
| City / Town: | Jerusalem |
| Country: | ISR |
| Postal Code: | 74036 |
| Exchange: | NSC |
| CEO: | Ron Babecoff |
| Employees: | 25 |
BiondVax Pharmaceuticals Ltd. announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.
Announced today that enrollment of 224 participants in a Phase 2b clinical trial, the study aims to show the dose sparing potential when given prior to avian vaccine.
All 224 participants successfully recruited in EU-sponsored trial
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will present at the Annual Roth Conference to be held March 13 - 16, 2016 at the Ritz Carlton Hotel in Dana Point, California.
Technical moves always precede Fundamental news and thought it important to point this out...something is in the offing and volume is always an indicator for me and I made a note to call the company.
BiondVax Pharmaceuticals (BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, announced today that its patent application in the United States, titled "Multimeric M
Broadens BiondVax's global intellectual property portfolio
BiondVax Pharmaceuticals announced that their patent application on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines was accepted in Israel.
The patent approval extends and strengthens BiondVax's international intellectual property portfolio
Although flu vaccinations are widely available, they only protect against a very specific strain of flu.
| Last Price 41.59 | Change $ 2.60 | Change % 6.67 | Tick N/A |
| Bid 22.00 | Bid Size 100.00 | Ask 47.00 | Ask Size 300.00 |
| Open 38.80 | High 42.49 | Low 36.10 | Prev Close 38.99 |
| Last Trade | Volume 160,145 | 52 Wk Hi 42.50 | 52 Wk Low 5.21 |
| Market Cap 426.5 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 10,255,349.00 | EPS (TTM) -3.88 | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 37 | 30 | 30 | 37 |
| Low Target Price Estimate | 37 | 30 | 30 | 37 |
| Mean Target Price Estimate | 37 | 30 | 30 | 37 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 06/01/18 | 05/07/18 | 05/07/18 | 06/01/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 15 | 2018-05-29 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 7 | 2018-05-01 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 232 | 2018-04-30 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 5 | 2018-04-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-03-29 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-03-21 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-03-14 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 32 | 2018-02-22 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 3 | 2018-02-22 |
| SC 13G/A | Amendment to the SC 13G filing | 9 | 2018-02-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait